{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["He X"],"funding":["Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Sciences","The National HighLevel Hospital Clinical Research Funding","Fujian Provincial Natural Science Foundation General Project","National Key Research and Development Program of China"],"pagination":["17562848241290663"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11528754"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["17"],"pubmed_abstract":["<h4>Background</h4>The efficacy of ustekinumab (UST) and infliximab (IFX) in Crohn's disease (CD) patients with intestinal stenosis remains uncertain.<h4>Objective</h4>This study aims to compare the efficacy of UST and IFX in the treatment of CD patients with intestinal stenosis.<h4>Design</h4>This was a retrospective and multicenter cohort study.<h4>Methods</h4>In this retrospective study, we included CD patients treated with IFX or UST at five centers. We assessed the clinical response rate at weeks 12 and 24, steroid-free clinical remission rate at weeks 24 and 52 for overall patients and those with stenosis, and objective examination (intestinal ultrasound and/or endoscopy) response rate at week 52 for stenosis patients.<h4>Results</h4>A total of 211 CD patients (106 IFX and 105 UST) w"],"journal":["Therapeutic advances in gastroenterology"],"pubmed_title":["Effectiveness comparison between ustekinumab and infliximab for Crohn's disease complicated with intestinal stenosis: a multicenter real-world study."],"pmcid":["PMC11528754"],"funding_grant_id":["2023J011593","2023YFC2507300","2022-I2M-C&amp;T-B-011","2022-PUMCH-C-018"],"pubmed_authors":["Yang H","Qian J","Hu Y","Zheng W","Li Y","Ding X","Zhan R","He X","Zhang X","Liu A","Chen Y","Wang Y","Ruan G","Sun J"],"additional_accession":[]},"is_claimable":false,"name":"Effectiveness comparison between ustekinumab and infliximab for Crohn's disease complicated with intestinal stenosis: a multicenter real-world study.","description":"<h4>Background</h4>The efficacy of ustekinumab (UST) and infliximab (IFX) in Crohn's disease (CD) patients with intestinal stenosis remains uncertain.<h4>Objective</h4>This study aims to compare the efficacy of UST and IFX in the treatment of CD patients with intestinal stenosis.<h4>Design</h4>This was a retrospective and multicenter cohort study.<h4>Methods</h4>In this retrospective study, we included CD patients treated with IFX or UST at five centers. We assessed the clinical response rate at weeks 12 and 24, steroid-free clinical remission rate at weeks 24 and 52 for overall patients and those with stenosis, and objective examination (intestinal ultrasound and/or endoscopy) response rate at week 52 for stenosis patients.<h4>Results</h4>A total of 211 CD patients (106 IFX and 105 UST) w","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024","modification":"2026-07-16T09:31:03.898Z","creation":"2025-04-06T15:23:31.155Z"},"accession":"S-EPMC11528754","cross_references":{"pubmed":["39493260"],"doi":["10.1177/17562848241290663"]}}